These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 27557616)

  • 1. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
    Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
    Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
    J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.
    Guo Z; Huang Y; Gong L; Gan S; Chan FL; Gu C; Xiang S; Wang S
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):451-460. PubMed ID: 29988099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.
    O'Farrell S; Sandström K; Garmo H; Stattin P; Holmberg L; Adolfsson J; Van Hemelrijck M
    BJU Int; 2016 Sep; 118(3):391-8. PubMed ID: 26497726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
    Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
    Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
    Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
    Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
    Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
    JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between Peripheral Thromboembolic Vascular Disease and Androgen Deprivation Therapy in Asian Prostate Cancer Patients.
    Lu YC; Huang CY; Yeh HM; Hong JH; Chang CH; Muo CH; Chung SD; Yang TK; Jaw FS; Chung CJ
    Sci Rep; 2019 Oct; 9(1):14231. PubMed ID: 31578427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden.
    Thorstenson A; Bratt O; Akre O; Hellborg H; Holmberg L; Lambe M; Bill-Axelson A; Stattin P; Adolfsson J
    Eur J Cancer; 2012 Jul; 48(11):1672-81. PubMed ID: 22386317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study.
    Crawley D; Garmo H; Rudman S; Stattin P; Zethelius B; Armes J; Holmberg L; Adolfsson J; Van Hemelrijck M
    BMJ Open; 2018 Mar; 8(3):e020787. PubMed ID: 29549214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
    Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
    Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.
    Thomsen FB; Bosco C; Garmo H; Adolfsson J; Hammar N; Stattin P; Van Hemelrijck M
    Acta Oncol; 2019 Jan; 58(1):110-118. PubMed ID: 30375907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.
    Hu JC; Williams SB; O'Malley AJ; Smith MR; Nguyen PL; Keating NL
    Eur Urol; 2012 Jun; 61(6):1119-28. PubMed ID: 22336376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
    Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.
    Azoulay L; Yin H; Benayoun S; Renoux C; Boivin JF; Suissa S
    Eur Urol; 2011 Dec; 60(6):1244-50. PubMed ID: 21908097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective cohort study of androgen deprivation therapy and the risk of diabetes in men with prostate cancer in Lithuania.
    Drevinskaite M; Patasius A; Kincius M; Urbonas V; Smailyte G
    BMJ Open; 2021 Jul; 11(7):e045797. PubMed ID: 34321292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review.
    Meng F; Zhu S; Zhao J; Vados L; Wang L; Zhao Y; Zhao D; Niu Y
    BMC Cancer; 2016 Mar; 16():180. PubMed ID: 26940836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.
    Thomsen FB; Sandin F; Garmo H; Lissbrant IF; Ahlgren G; Van Hemelrijck M; Adolfsson J; Robinson D; Stattin P
    Eur Urol; 2017 Dec; 72(6):920-928. PubMed ID: 28711383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.